Medidata Partners with East Clinical Center of Oncology and Gobio Medical Group to Accelerate Digital Transformation in Clinical Trials
Shanghai, China – Medidata, a wholly owned subsidiary of Dassault Systèmes (France), announced a groundbreaking integrated strategic partnership with the Eastern Clinical Oncology Research Center and Gaobo Medical Group. As its preferred partner, Medidata will jointly explore the digital transformation of clinical research for new oncology drugs in China, promoting the clinical application of innovative digital technologies such as Rave EDC (Electronic Data Capture), Decentralized Clinical Trials (DCT), and Medidata AI.
On June 13, the agreement signing ceremony was grandly held at the Dassault Systèmes Asia Pacific headquarters in Lujiazui, Shanghai. Professor Li Jin, Director of the Department of Oncology at Shanghai East Hospital affiliated with Tongji University and Chairman of the Dongfang Clinical Oncology Research Center; Dr. Tian Zhenglong, Vice President of the Clinical Research Center and Chief Operating Officer of Gaobo Medical Group; Ms. Li Wei, Vice President of Dassault Systèmes’ Life Sciences Division and General Manager of Medidata Greater China; along with other relevant representatives, attended the ceremony and delivered speeches.
Signing Ceremony for the Three-Party Representatives
From left to right: Li Wei, Vice President of Dassault Systèmes’ Life Sciences Division and General Manager of Medidata Greater China; Professor Li Jin, Director of the Department of Oncology at Shanghai East Hospital affiliated with Tongji University and Chairman of the East Clinical Oncology Research Center; Dr. Tian Zhenglong, Vice President and Chief Operating Officer of the Clinical Research Center at GoBroad Healthcare Group
Group Photo of Representatives from the Three Parties and Member Units of the Eastern Clinical Oncology Research Center
Front row, from left to right: Li Wei, Vice President of Dassault Systèmes’ Life Sciences Division and General Manager of Medidata Greater China; Professor Li Jin, Director of the Department of Oncology at Shanghai East Hospital affiliated with Tongji University and Chairman of the East Clinical Oncology Research Center; Dr. Tian Zhenglong, Vice President and Chief Operating Officer of the Clinical Research Center at GoBroad Healthcare Group
Back row, from left to right: Wu Ning, Director of the Department of Oncology at Shanghai Pudong New Area Gongli Hospital; Qin Juan, Director of the Office of the Oriental Clinical Oncology Research Center; Sun Yuping, Deputy Director of the Institution and Director of the Phase I Clinical Research Center at Shandong Cancer Hospital; Zhang Min, Senior Director at Shida (Shanghai) Pharmaceutical Technology Co., Ltd.
In recent years, drug clinical trial centers across China have experienced rapid development, becoming a critical hub for facilitating the translation of pharmaceutical research achievements and exploring the application of innovative clinical trial technologies. Based on this strategic collaboration, the 42 member institutions of the Orient Clinical Oncology Research Center and medical facilities under the Gaobo Medical Group will adopt Medidata’s industry-leading Rave EDC as their preferred electronic data capture (EDC) solution for clinical trials. Initial implementation will focus on Phase I oncology drug trials to optimize data management, comprehensively improve the efficiency of data collection, and enhance the quality and integrity of trial data. Building on this foundation, the Medidata Unified Platform will also provide additional innovative solutions throughout the entire trial lifecycle, including Decentralized Clinical Trials (DCT) and Medidata AI. These measures will further optimize trial management and operations, safeguard the safety and experience of enrolled patients, and ensure more efficient and secure advancement of clinical trials.
Professor Li Jin, Director of the Department of Oncology at Shanghai East Hospital Affiliated to Tongji University and Chairman of the East Clinical Oncology Research Center“The biopharmaceutical industry is a vital pillar of China’s economic development and is closely intertwined with the country’s future. Since 2014, the number of biopharmaceutical companies in China has grown significantly, with close collaboration among various stakeholders continuously driving innovation in the sector. Today, we are delighted to have reached this strategic partnership. Medidata’s patient-centric philosophy aligns seamlessly with our vision, and the reliability, accuracy, and security of its EDC solution will help enable higher-quality and more efficient clinical trials. We look forward to working closely with Medidata to accelerate digital exploration in future clinical trials, turning innovation into tangible results and contributing to the Healthy China initiative.”
Dr. Tian Zhenglong, Vice President and Chief Operating Officer of the Clinical Research Center at Gaobo Medical Group“He remarked, ‘With the continuous improvement of domestic regulations on clinical trial data management for pharmaceuticals, the era of digital intelligence in clinical trials has arrived. In recent years, Gaobo Medical Group has actively embraced digital innovation technologies and accumulated extensive collaborative experience with Medidata. Medidata’s unified platform, clinically validated for its high accuracy and efficiency, leads the industry by helping to fully unlock the value of clinical data and drive precise and efficient clinical R&D. We are delighted to further deepen our strategic partnership with Medidata, propelling drug clinical research into the digital intelligence track. We are confident that Medidata will help us achieve stable and efficient clinical trial data collection, management, and reporting, provide superior data insights, and empower innovative drug development.’”
Ms. Li Wei, Vice President of Dassault Systèmes’ Life Sciences Division and General Manager of Medidata Greater Chinastated: “We are delighted to establish this new collaborative model with the Hospital Alliance. This partnership not only reflects the trust and recognition of Medidata’s unified platform solution by various stakeholders in China’s healthcare industry, but also underscores Medidata’s commitment to actively promoting collaborative innovation and mutual benefit in the Chinese market. We will establish a close communication mechanism with the Hospital Alliance, building on the solid foundation of Rave EDC implementation at research centers across different regions. Through flexible cooperation models, we will continue to advance the digital transformation of clinical trials and facilitate the adoption and application of more innovative technologies. Looking ahead, we anticipate that Medidata’s cutting-edge digital intelligence solutions and global practical experience will help more domestic research centers achieve new breakthroughs in innovative drug development, ultimately benefiting more patients.”
Medidata is a wholly owned subsidiary of Dassault Systèmes. The 3DEXPERIENCE platform from Dassault Systèmes is dedicated to leading the digital transformation of the life sciences industry in the era of personalized medicine, serving as the first scientific business platform that covers the entire end-to-end process from research to commercialization.
The Eastern Clinical Oncology Research Center (ECCO) is a non-governmental, non-profit academic organization voluntarily formed by clinical oncology professionals in China, dedicated to the treatment of cancer, as well as conducting academic research and exchanges. ECCO comprises 48 renowned oncology experts and scholars from 42 major Grade A tertiary hospitals across China, aiming to actively promote multi-center clinical trials and academic exchanges, thereby serving as an academic organization that drives the development of clinical oncology in China.
Gaobo Medical Group has always adhered to the philosophy of "putting patient needs first," with a mission and vision to pursue excellence in diagnosis and treatment, break through innovative technologies, and create possibilities for life. It is committed to building a clinically driven innovative medical technology platform.
Founded in 2017, the Group focuses on clinical diagnosis and treatment, clinical research, reference laboratories, and informatization. By partnering with a cohort of top medical experts possessing extensive clinical experience and robust scientific research capabilities, the Group has jointly established a unique “Academic Research Organization” (ARO). Its strategic objective is to build an innovative healthcare ecosystem encompassing “clinical discovery–basic scientific research–industrial translation–clinical application,” thereby enhancing the efficiency and quality of development in the biopharmaceutical industry. As a pioneer in exploring the research hospital model in China, Gaobo Group currently operates seven hospitals in Beijing, Shanghai, and Guangzhou.
Medidata is leading the digital transformation of life sciences, bringing hope to millions of patients. Medidata helps generate evidence and insights, empowering pharmaceutical companies, biotechnology firms, medical device manufacturers, diagnostic companies, and academic researchers to accelerate value creation, minimize risks, and optimize outcomes. As a globally trusted platform for clinical development, commercialization, and real-world data, the Medidata platform has been adopted by more than 2,100 customers and partners worldwide, with over 1,000,000 registered users. Medidata is a Dassault Systèmes company (Euronext Paris: FR0014003TT8, DSY.PA), headquartered in New York City, with subsidiaries in numerous countries and regions around the world to meet local customer needs. In 2015, Medidata officially entered the Chinese market, establishing branches in Beijing and Shanghai to provide prompt and professional services to its Chinese customers.
As an industrial software provider delivering 3DEXPERIENCE solutions to customers worldwide, Dassault Systèmes is committed to serving as a catalyst for human progress. We empower enterprises and clients with collaborative 3D virtual spaces to drive sustainable innovation. By leveraging the Dassault Systèmes 3DEXPERIENCE platform and industry-specific solutions, our customers create virtual twins of the real world, thereby redefining their product creation, production, and full lifecycle management processes to build a more sustainable world. The experience economy prioritizes a human-centric approach, benefiting consumers, patients, and citizens. Dassault Systèmes delivers value to more than 300,000 customers of varying industries and sizes across over 150 countries.
Dassault Systèmes retains all rights. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA, and SOLIDWORKS are registered trademarks of Dassault Systèmes (a European company incorporated in Versailles, France, under registration number 322 306 440) or its subsidiaries in the United States and/or other countries.